Prion diseases are caused by the accumulation of aberrantly folded prion proteins, which induce neurotoxicity and relentless neurodegeneration. Targeting the expression of PrP has long been hypothesized as a promising disease-modifying strategy, but delivering effective and brain-wide suppression of this protein has posed enormous challenges. The siRNA candidate under investigation functions by binding to and cleaving the messenger RNA (mRNA) that encodes the prion protein, thus preventing the cellular machinery from producing the harmful protein in excess. Prior research utilizing animal models demonstrated that partial reduction of PrP levels significantly delays disease onset and progression, supporting the translational potential of RNA interference-based therapeutics for human prion disease.

This novel divalent siRNA compound is structurally unique—it consists of two identical siRNA units chemically linked to enhance distribution within the brain tissue compared to single siRNA molecules. This divalent design was spearheaded by the lab of Anastasia Khvorova at UMass Chan Medical School. By achieving broader CNS penetration and durable suppression of the prion protein, this molecule overcomes key pharmacodynamic hurdles that have hampered siRNA therapies in neurological disorders. The clinical trial, known as PRiSM (PrP-targeting siRNA Safety & Mechanism Study), represents the first human test of this technology with a focus on both symptomatic patients and those monitored observationally.

Prion Therapeutic Science program leaders Eric Minikel and Sonia Vallabh, who have a deeply personal connection to the disease through Vallabh’s genetic predisposition, have driven this initiative with a strong emphasis on transparency and open science. Unlike traditional drug developers, they have publicly shared their FDA Investigational New Drug (IND) application data, setting a new standard for openness in neurodegenerative disease research. This unusual level of transparency reflects their conviction that accelerating scientific progress and fostering collaboration is vital for a field that has historically seen few therapeutic breakthroughs.

Preclinical studies published as a recent bioRxiv preprint provide compelling evidence of the therapeutic promise. In a mouse model of prion disease, a single intracerebroventricular dose of the divalent siRNA led to an approximately 49% reduction of brain prion protein levels. Impressively, this molecular knockdown translated into a 64% extension of survival time in symptomatic animals, underscoring the potential clinical benefit of the approach. These results laid the groundwork for FDA clearance of the IND in March 2025, a critical regulatory milestone rarely achieved without the backing of larger pharmaceutical companies.

The upcoming clinical trial is facilitated by NeuroNEXT, a National Institute of Neurological Disorders and Stroke (NINDS) program that supports early-phase neuroscience clinical research. NeuroNEXT provides not only financial backing but also the infrastructure necessary to conduct rigorous trials, including experienced sites, a coordinating center at Massachusetts General Hospital’s Neurology Department, and a comprehensive data and statistics center at the University of Iowa. This collaborative network is designed to accelerate the translation of promising therapies into validated clinical interventions.

The trial will enroll an initial cohort of 15 patients with symptomatic prion disease, who will receive the siRNA through lumbar puncture, allowing direct delivery into the cerebrospinal fluid and the central nervous system. Dosing will be escalated with later enrollees to establish safety parameters and determine the maximum tolerated dose. Parallel to this, an observational arm comprising 15 additional symptomatic patients will monitor disease progression without intervention, providing essential natural history data. Investigators also hope to expand enrollment to pre-symptomatic gene carriers in subsequent phases, an innovative approach that could potentially enable prophylactic treatment.

The leadership team, incorporating Khvorova’s expertise in RNA therapeutics and the prion-focused research vision of Minikel and Vallabh, is committed to not only advancing this specific candidate but also pioneering a new model of clinical trial conduct characterized by ethical rigor and data sharing. Khvorova emphasizes that this trial embodies a visionary integration of cutting-edge science and patient-centered ethics, setting a precedent for future efforts in neurodegenerative disease drug development. This ethos reflects a deep commitment to maximizing the scientific yield while rapidly disseminating knowledge gained to benefit the broader research community.

In parallel with this siRNA candidate, the Broad Institute team continues to explore various therapeutic strategies, including epigenetic modulation and gene editing technologies, aimed at further modulating prion protein expression and addressing disease pathology. This multipronged approach underscores the complexity of prion disease biology and the necessity for innovative interventions that can be tailored to patient needs. The phase 1 trial is thus a crucial step in a larger pipeline of experimental therapeutics under active investigation.

The initiation of this trial follows on the heels of another clinical study launched in 2023 by Ionis Pharmaceuticals, testing a separate antisense oligonucleotide drug candidate (ION717). While encouraging, both studies affirm the urgent need for new therapies for prion diseases. Patients, families, and clinicians affected by these invariably lethal disorders are hopeful but cautious, awaiting evidence not just of safety but meaningful clinical benefit, a goal that remains elusive in prion therapeutics.

For the prion disease community and scientific stakeholders alike, this trial symbolizes hope and innovation. The openly shared trial protocols and results promise to catalyze advancements not only for prion diseases but also for the broader field of RNA-based therapies for neurodegeneration. By publicly documenting their challenges and successes, the investigators are fostering an unprecedented culture of transparency that could redefine how future treatments for rare neurodegenerative disorders are developed and delivered.

To gain further insight into the trial and ongoing research efforts, information is accessible through ClinicalTrials.gov and CureFFI.org, where frequent updates will provide transparency for patients, clinicians, and researchers. Additionally, the CJD Foundation remains a valuable resource for those seeking support and education regarding prion diseases. As the trial progresses, the scientific community will watch closely, hopeful that this innovative siRNA candidate may finally offer a therapeutic lifeline for a group of disorders long shrouded in fatalism and despair.

Subject of Research: Therapeutic development of divalent siRNA targeting prion protein RNA for treatment of prion disease.

Article Title: First Human Trial Launches for Novel siRNA Therapeutic Slowing Prion Disease Progression

News Publication Date: 2025

Web References:

• Clinical trial registry: https://clinicaltrials.gov/study/NCT07444580
• CureFFI.org patient and scientific resource hub: http://cureffi.org/
• Preprint publication: https://www.biorxiv.org/content/10.1101/2024.12.05.627039v6
• Ionis Pharmaceuticals trial: https://clinicaltrials.gov/study/NCT06153966

References: IND filing published by investigators (https://www.cureffi.org/2025/04/14/open-ind-whats-next/)

Keywords: Prion disease, small interfering RNA, siRNA therapeutics, neurodegenerative disorders, clinical trial, RNA interference, prion protein suppression, divalent siRNA, translational neuroscience, NeuroNEXT, FDA IND, gene therapy

Alzheimer’s disease manifests through the accumulation of sticky amyloid beta proteins that aggregate into plaques, catalyzing a cascade of neurodegeneration and cognitive decline. While microglia cells normally act as the brain’s custodians, clearing detrimental cellular debris, their efficacy diminishes as disease progresses, burdened by overwhelming amyloid loads. To circumvent the limitations posed by microglia dysfunction, researchers turned to astrocytes, which constitute the majority of brain cells and are central to maintaining neural homeostasis. By genetically modifying these astrocytes with a bespoke CAR, delivered through a benign viral vector, they endowed them with a precise homing mechanism that enables them to recognize and engulf amyloid beta plaques directly.

This strategy draws inspiration from successful CAR T-cell therapies in oncology but is adapted here to harness the brain’s intrinsic immune environment. Unlike immune cells in the bloodstream, astrocytes reside within the central nervous system and are well-positioned to act as “super cleaners” in situ. Upon intravenous administration of the viral vector carrying the CAR gene, astrocytes express the receptor on their surface. This engineered receptor binds selectively to amyloid beta proteins, guiding the astrocytes to target plaques without compromising other essential brain functions. The result is a potent and focused clearance of toxic aggregates with minimal invasiveness.

Experimental validation of this approach was conducted in genetically modified mice harboring mutations analogous to those increasing Alzheimer’s risk in humans. When administered to young mice prior to plaque formation, a single injection successfully prevented the onset of amyloid beta deposition over a three-month period. Remarkably, when introduced to older mice already exhibiting extensive amyloid burden, the therapy halved the existing plaques, demonstrating both preventative and therapeutic potential. This dual efficacy underscores the transformative nature of CAR-astrocyte therapy in halting or reversing early-to-mid stage Alzheimer’s pathology.

The technical innovation of the study lies in the precise gene engineering and delivery system. Utilizing a non-pathogenic viral vector, the researchers ensured the stable integration and expression of the CAR gene specifically in astrocytes. This genetic reprogramming allowed astrocytes to extend beyond their ordinary maintenance roles and become active phagocytes targeting amyloid beta aggregates. The CAR construct itself was meticulously designed to optimize binding affinity to the amyloid epitopes while minimizing off-target interactions, reducing risks of collateral damage to neurons or other glial cells.

Senior author Dr. Marco Colonna emphasizes that this represents the first credible attempt to reprogram astrocytes for targeted amyloid clearance in vivo, pioneering an entirely new facet of neuroimmunology therapeutics. While the findings hold tremendous promise, further studies are needed to refine the anatomical targeting, regulate therapeutic dosing, and fully delineate safety profiles. Potential side effects, such as unintended inflammatory responses or astrocyte depletion, must be carefully assessed before clinical translation.

Co-author Dr. David Holtzman highlights a key advantage of this therapy compared to monoclonal antibodies: the convenience and durability conferred by a single injection. Existing antibody infusions require repeated administration every few weeks, posing logistical challenges and increased healthcare costs. In contrast, the persistent presence of CAR-astrocytes within brain tissue could provide long-lasting amyloid surveillance and clearance, decreasing treatment burden substantially.

Looking ahead, the research team envisions further engineering of the CAR to recognize distinct pathological protein variants or to modulate astrocyte behavior dynamically. One intriguing possibility is retargeting the CAR-astrocytes to attack malignant cells within the central nervous system, thereby creating a novel immunotherapy platform not only for neurodegenerative diseases but also for brain tumors. This could revolutionize therapeutic paradigms for a range of currently intractable CNS disorders.

The development of the CAR-astrocyte platform also holds significant implications for understanding brain immune metabolism and homeostasis. Astrocytes, previously characterized primarily as support cells regulating neurotransmitter balance and ion exchange, have been recast here as versatile immuno-effector cells. This shift in perspective deepens comprehension of the brain’s intrinsic capacity for self-repair and clearance, potentially uncovering new targets for intervention.

The team’s patent-pending technology represents a strategic advancement bridging neurobiology and immunotherapy. Backed by major institutions such as the NIH and the Cure Alzheimer’s Fund, the study embodies a collaborative effort pushing the frontlines of Alzheimer’s research. As the global burden of Alzheimer’s escalates with aging populations, innovations like CAR-astrocytes offer a beacon of hope, promising to delay or even reverse cognitive decline through precision cellular engineering.

In conclusion, the introduction of CAR-astrocyte immunotherapy signals a potentially seismic shift in the battle against Alzheimer’s disease. This approach marries cutting-edge genetic engineering with deep neurobiological insight to transform the brain’s cleaning machinery from passive bystanders into active combatants against toxic protein pathology. With further optimization and thorough clinical evaluation, CAR-astrocytes may soon emerge as a cornerstone therapy, offering improved efficacy, reduced treatment frequency, and enhanced quality of life for millions facing the scourge of neurodegeneration.

Subject of Research: Animals

Article Title: Targeting amyloid-β pathology by chimeric antigen receptor astrocyte (CARA) therapy

News Publication Date: 5-Mar-2026

Web References: 10.1126/science.ads3972

Keywords: Neurodegenerative diseases, Alzheimer’s disease, amyloid beta, astrocytes, chimeric antigen receptor, CAR therapy, immunotherapy, brain plaques, neuroimmunology, cellular engineering

The crux of this clinical trial was evaluating zonisamide — an antiepileptic drug with previously reported benefits in Parkinson’s disease — to determine whether it could decelerate or halt the progression in patients who are in the prodromal phase of LBD. This early stage, often preceding full-blown dementia with Lewy bodies (DLB) or Parkinson’s disease dementia, offers a critical window for intervention, and identifying means to alter the disease course at this juncture is vital for significantly improving patient outcomes. The importance of focusing on prodromal LBD cannot be overstated, as existing therapeutic strategies primarily address symptoms rather than underlying pathology.

The trial design was rigorous, involving a randomized, double-blind, placebo-controlled framework that enhances the robustness and reliability of the results. Participants were carefully selected based on stringent clinical and biomarker criteria indicative of prodromal LBD, ensuring that the findings are applicable to the critical early disease stage. Moreover, the use of innovative neuroimaging techniques, alongside comprehensive cognitive and motor assessments, provided a multidimensional evaluation of zonisamide’s effects. Such an integrative methodology is crucial to discerning subtle neuroprotective effects that might be elusive in more traditional clinical assessments.

One of the significant observations from this pilot study was zonisamide’s apparent ability to improve motor function metrics without exacerbating psychiatric or cognitive symptoms, something that often complicates treatment in LBD. By selectively targeting pathways implicated in dopaminergic dysfunction—central in the pathology of Lewy body disease—zonisamide demonstrated a favorable safety profile and potential neuroprotective properties. This is a promising indicator that the drug may not only alleviate symptoms but also intervene in the underlying disease mechanisms that have so far remained impervious to pharmacological intervention.

Also noteworthy is how the trial addressed the complex challenge of patient heterogeneity in neurodegenerative diseases. The prodromal phase of LBD is notoriously difficult to pinpoint precisely due to overlapping clinical features with Parkinson’s disease and Alzheimer’s disease, as well as the fluctuating nature of symptoms. By leveraging advanced biomarkers and clinical staging criteria, the researchers could more accurately delineate the patient cohort, which bolsters the applicability of zonisamide as a targeted therapy rather than a one-size-fits-all solution. This personalized approach positions the research within the broader paradigm shift towards precision medicine in neurology.

The significance of these findings lies not just in the immediate potential of zonisamide but in setting a precedent for repurposing existing drugs with known safety profiles for novel indications in neurodegeneration. As drug development pipelines face increasing costs and complexities, the strategy to assess the disease-modifying potential of already-approved medications accelerates translational research while ensuring patient safety. The study by Hiraga et al. exemplifies this translational paradigm, paving the way for subsequent larger-scale trials that could ultimately redefine the clinical management of Lewy body disease.

From a mechanistic standpoint, zonisamide’s multifaceted pharmacology may confer its benefits. Beyond its antiepileptic properties, it modulates various ion channels and neurotransmitter systems, possibly ameliorating mitochondrial dysfunction and oxidative stress — processes intrinsically linked to Lewy body pathology. The authors discuss how these mechanistic insights support the observed clinical improvements, hinting at a broader therapeutic potential that could extend beyond LBD to other synucleinopathies. This opens intriguing avenues for future investigation into shared pathogenic pathways among neurodegenerative disorders.

The trial also underscores the evolving landscape of prodromal neurodegenerative research by emphasizing the importance of symptom biomarkers such as REM sleep behavior disorder, subtle cognitive impairment, and autonomic dysfunction, all of which precede more overt Lewy body disease manifestations. Early identification and enrollment of such patient populations into clinical trials are crucial steps toward establishing effective interventions. The researchers’ ability to detect meaningful treatment signals at this nascent stage highlights the sophistication of current diagnostic tools and the increasing feasibility of prodromal-stage therapeutic development.

Importantly, the study’s design incorporated comprehensive assessments of quality of life and functional status in addition to standard neurological outcomes. This multidimensional focus acknowledges that the ultimate goal of disease-modifying treatments extends beyond mere symptom control to maintaining patient autonomy and daily living capacities. By demonstrating that zonisamide potentially supports these broader clinical goals, the study positions the drug as a viable candidate for holistic patient care approaches in neurodegenerative medicine.

Despite the promise, the authors cautiously acknowledge limitations inherent in a pilot trial of this scale, including a relatively small sample size and the short duration of follow-up. These factors necessitate further validation through larger, longer-term studies that could confirm the drug’s efficacy and safety profile across diverse populations. Additionally, elucidating the optimal dosing regimens and treatment windows will be imperative to maximize therapeutic benefit while minimizing adverse effects, a balance that remains challenging in chronic neurological conditions.

In the broader context of neurodegenerative disease research, this trial marks a pivotal moment by translating insights from preclinical models and Parkinson’s disease experiences to the realm of Lewy body disease. The convergence of multidisciplinary expertise — ranging from neurology, pharmacology, biomarker development, and neuroimaging — in this study exemplifies the comprehensive approach required to tackle complex diseases. Such integrative efforts are crucial for developing effective disease-modifying therapies, as the multifactorial nature of neurodegeneration demands nuanced, multi-targeted strategies.

Moreover, the findings generate optimism for the future of therapeutic interventions targeting synucleinopathies at large. Considering the shared molecular underpinnings across Parkinson’s disease, multiple system atrophy, and Lewy body dementia, research leveraging agents like zonisamide could potentially spearhead a new era of cross-cutting neuroprotective therapies. This trial thus serves as a foundation, encouraging expanded research into overlapping pathological processes and the targeting of convergent pathways to achieve broader clinical impact.

The study also triggers important conversations concerning the integration of clinical trial research into routine clinical practice, particularly with regard to identifying at-risk individuals earlier. As health systems increasingly embrace biomarker-driven diagnostics and personalized medicine, the emergence of disease-modifying agents like zonisamide would necessitate new models of care focused on early detection and timely therapeutic engagement. This shift has profound implications for healthcare delivery, resource allocation, and patient education strategies moving forward.

In summary, Hiraga and colleagues have illuminated a promising path forward in the fight against Lewy body disease by demonstrating that zonisamide holds potential not only for symptomatic relief but also for disease modification in the prodromal phase. Through meticulous trial design and cutting-edge biomarker utilization, this research offers hope for altering the trajectory of a notoriously challenging neurodegenerative disorder. As the neurodegenerative research community eagerly anticipates subsequent larger trials, the implications of these findings reverberate with the possibility of transforming clinical outcomes for millions impacted by this devastating disease.

This novel evidence providing a foothold for early pharmacological intervention in prodromal Lewy body disease could very well be the harbinger of a new era in neurology—a future where devastating neurodegenerative diseases are intercepted before irreversible damage accrues, redefining hope for patients and clinicians alike.

Subject of Research: Phase II clinical trial investigating the disease-modifying potential of zonisamide in prodromal Lewy body disease.

Article Title: Phase II pilot randomized trial of zonisamide for disease modification in prodromal Lewy body disease.

Article References:
Hiraga, K., Hattori, M., Tamakoshi, D. et al. Phase II pilot randomized trial of zonisamide for disease modification in prodromal Lewy body disease. npj Parkinsons Dis. 11, 322 (2025). https://doi.org/10.1038/s41531-025-01198-3

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41531-025-01198-3